numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System
- AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysia
- numares Health appoints BioD Medica for local distribution
- MDA filing for additional CE-marked product is currently in progress
Regensburg, Germany, 16 December 2025 – numares Health (“numares”), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, today announces the expansion of its global footprint into the ASEAN region having received regulatory approval in Malaysia and subsequently securing its first contract for the AXINON® LDLp Test System (“AXINON”) with BioD Medica, who specialise in introducing medical devices and healthcare technology into Malaysia and Singapore.
